Figure 1.

Phenotypic correlates, molecular features, and survival outcomes of SF3B1^MTCMML, SF3B1^WTCMML, and SF3B1^MTMDS-RS. (A-B) Mutational distribution of myeloid-relevant mutations in SF3B1^MT CMML and SF3B1^WT CMML (A) and SF3B1^MT CMML and SF3B1^MT MDS-RS (B). Asterisks denote statistically significant differences between the 2 groups. (C) Median VAF burdens of SF3B1 mutations in SF3B1^MT CMML and SF3B1^MT MDS-RS. (D) Amino acid changes in SF3B1 secondary to SF3B1 mutations in CMML and MDS-RS. (E) Pertinent outcomes including OS and acute leukemia–free survival (ALFS) among SF3B1^MT CMML, SF3B1^WT CMML, and SF3B1^MT MDS-RS patients.